Price alert —
Sign in to get a one-time email the moment IDXX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · IDXX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.1B | $0.3B | $0.4B | $0.2B | 24.4% | 31.8% |
| 2025-12-31 | $1.1B | $0.2B | $0.3B | $0.3B | 22.8% | 28.9% |
| 2025-09-30 | $1.1B | $0.3B | $0.4B | $0.4B | 24.8% | 32.1% |
| 2025-06-30 | $1.1B | $0.3B | $0.4B | $0.2B | 26.5% | 33.6% |
| 2025-03-31 | $1.0B | $0.2B | $0.3B | $0.2B | 24.3% | 31.7% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare IDXX vs peers
Line IDXX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with IDXX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-05 | 3.47 | 3.41 | +1.7% | +2.9% |
| 2026-02-02 | 3.08 | 2.94 | +4.8% | -1.1% |
| 2025-11-03 | 3.40 | 3.15 | +8.1% | -0.1% |
| 2025-08-04 | 3.63 | 3.30 | +10.0% | -6.0% |
| 2025-05-01 | 2.96 | 2.84 | +4.1% | +0.1% |
| 2025-02-03 | 2.62 | 2.40 | +9.2% | -0.8% |
| 2024-10-31 | 2.80 | 2.69 | +4.3% | +2.5% |
| 2024-08-06 | 3.02 | 2.87 | +5.2% | -0.5% |
| 2024-05-01 | 2.81 | 2.68 | +4.8% | +1.7% |
| 2024-02-05 | 2.32 | 2.12 | +9.4% | -0.9% |
| 2023-11-01 | 2.53 | 2.37 | +6.7% | +6.1% |
| 2023-08-01 | 2.67 | 2.47 | +8.2% | -2.5% |
| 2023-05-02 | 2.55 | 2.43 | +4.9% | +2.5% |
| 2023-02-06 | 2.05 | 1.92 | +6.5% | +4.6% |
| 2022-11-01 | 2.15 | 2.04 | +5.5% | -5.6% |
| 2022-08-02 | 1.56 | 1.63 | -4.1% | +2.0% |
| 2022-05-04 | 2.27 | 2.25 | +1.0% | -6.4% |
| 2022-02-02 | 1.89 | 1.72 | +9.9% | +0.9% |
| 2021-11-02 | 2.03 | 1.91 | +6.1% | -0.3% |
| 2021-07-30 | 2.34 | 2.04 | +14.6% | +0.0% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| IDXX ★ | $45B | 41.8 | 34.4 | 10.1 | 29.5 | 28.9 | 62.1% | 14.3% | 17.2% | 1.76% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 41.93%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 8,365,553 | 10.61% |
| Vanguard Capital Management LLC | 5,182,507 | 6.57% |
| Vanguard Portfolio Management LLC | 3,910,863 | 4.96% |
| State Street Corporation | 3,674,185 | 4.66% |
| Invesco Ltd. | 3,349,677 | 4.25% |
| Geode Capital Management, LLC | 2,660,999 | 3.37% |
| BAMCO Inc. | 1,633,367 | 2.07% |
| Bank Of New York Mellon Corporation | 1,504,532 | 1.91% |
| Fundsmith LLP | 1,465,786 | 1.86% |
| Morgan Stanley | 1,315,954 | 1.67% |
Insider activity · 90d
12 buys / 0 sells · ratio 12.0 · Finnhub
- FENNELL GEORGE M 0
- FENNELL GEORGE F 10,433 @ $566.79
- FENNELL GEORGE M 10,717
- Peacock Karen BUY 234
- Peacock Karen BUY 525
- SAMAD SAM BUY 1,354
- SAMAD SAM BUY 525
- Britt Irene Chang BUY 753
- Britt Irene Chang BUY 525
- Vandebroek Sophie V. BUY 234
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-02 | FORM 4 | view · |
| 8-K | 2026-05-15 | 8-K | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 4 | 2026-05-11 | FORM 4 | view · |
| 10-Q | 2026-05-05 | 10-Q | view · |
| 8-K | 2026-05-05 | FORM 8-K | view · |
| 4 | 2026-05-04 | FORM 4 | view · |
| DEF 14A | 2026-03-27 | DEF 14A | view · |
| 8-K | 2026-03-26 | FORM 8-K | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-05 | FORM 4 | view · |
| 4 | 2026-03-02 | FORM 4 | view · |
| 4 | 2026-02-27 | FORM 4 | view · |
| 10-K | 2026-02-20 | 10-K | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 8-K | 2026-02-13 | 8-K | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 8-K | 2026-02-02 | FORM 8-K | view · |
| 8-K | 2026-01-13 | FORM 8-K | view · |
| 4 | 2025-12-03 | FORM 4 | view · |
| 8-K | 2025-11-13 | FORM 8-K | view · |
| 4 | 2025-11-10 | FORM 4 | view · |
| 4 | 2025-11-03 | FORM 4 | view · |
| 10-Q | 2025-11-03 | 10-Q | view · |
| 8-K | 2025-11-03 | FORM 8-K | view · |
| 8-K | 2025-10-07 | FORM 8-K | view · |
| 4 | 2025-09-04 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-09-03 | FORM 4 | view · |
| 4 | 2025-08-26 | FORM 4 | view · |
| 4 | 2025-08-14 | FORM 4 | view · |
| 4 | 2025-08-13 | FORM 4 | view · |
| 4 | 2025-08-12 | FORM 4 | view · |
| 4 | 2025-08-12 | FORM 4 | view · |
| 4 | 2025-08-11 | FORM 4 | view · |
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clin…
Options picks · IDXX
ITM + OTM ideas from the latest scanLoading…
Congress trades · IDXX
STOCK Act disclosuresLoading…
SEC filings & insiders · IDXX
EDGAR · liveLoading…
Holders · IDXX
Institutions & insider activityLoading…